Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $32.60
by Renee Jackson · The Cerbat GemShares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.60.
A number of analysts recently commented on KALV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC increased their target price on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Citizens Jmp reduced their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. HC Wainwright boosted their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 28th.
Get Our Latest Stock Analysis on KALV
Insider Activity
In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the business’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total value of $2,960,232.75. Following the completion of the transaction, the insider directly owned 5,129,340 shares in the company, valued at approximately $86,942,313. The trade was a 3.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $156,229.38. Following the completion of the transaction, the chief executive officer owned 442,883 shares of the company’s stock, valued at $6,895,688.31. The trade was a 2.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On KalVista Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals during the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $63,000. Finally, Truvestments Capital LLC lifted its stake in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares in the last quarter.
KalVista Pharmaceuticals Price Performance
KalVista Pharmaceuticals stock opened at $19.90 on Wednesday. The stock has a market cap of $1.02 billion, a PE ratio of -5.04 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock’s fifty day moving average is $16.44 and its two-hundred day moving average is $14.64. KalVista Pharmaceuticals has a 1-year low of $9.23 and a 1-year high of $21.31.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.